Vicadrostat is under clinical development by Boehringer Ingelheim International and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure).
Cybin Reports Second Quarter Financial Results and Recent Business Highlights | Psychedelic Invest
–Announced unprecedented positive Phase 2 interim data for CYB003, its proprietary deuterated psilocybin analog, in major depressive disorder – – Announced closing of a unit